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Abstract
Identification and characterization of the genetic variants underlying type 2 diabetes susceptibility
can provide important understanding of the etiology and pathogenesis of type 2 diabetes. We
previously identified strong evidence of linkage for type 2 diabetes on chromosome 22 among
3,383 Hypertension Genetic Epidemiology Network (HyperGEN) participants from 1,124
families. The checkpoint 2 (CHEK2) gene, an important mediator of cellular responses to DNA
damage, is located 0.22 Mb from this linkage peak. In this study, we tested the hypothesis that the
CHEK2 gene contains one or more polymorphic variants that are associated with type 2 diabetes
in HyperGEN individuals. In addition, we replicated our findings in two other Family Blood
Pressure Program (FBPP) populations and in the population-based Atherosclerosis Risk in
Communities (ARIC) study. We genotyped 1,584 African-American and 1,531 white HyperGEN
participants, 1,843 African-American and 1,569 white GENOA participants, 871 African-
American and 1,009 white GenNet participants, and 4,266 African-American and 11,478 white
ARIC participants for four single nucleotide polymorphisms (SNPs) in CHEK2. Using additive
models, we evaluated the association of CHEK2 SNPs with type 2 diabetes in participants within
each study population stratified by race, and in a meta-analysis, adjusting for age, age2, sex, sex-
by-age interaction, study center, and relatedness. One CHEK2 variant, rs4035540, was associated
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with an increased risk of type 2 diabetes in HyperGEN participants, two replication samples, and
in the meta-analysis. These results may suggest a new pathway in the pathogenesis of type 2
diabetes that involves pancreatic beta-cell damage and apoptosis.
Keywords
CHEK2 gene; CHEK2 SNPs; Type 2 diabetes; Family Blood Pressure Program; Atherosclerosis
Risk in Communities Study
Introduction
Type 2 diabetes is a major public health problem. Complications from diabetes are currently
the sixth leading cause of death in the United States [1] and account for a large proportion of
health care costs [2]. Approximately, 90–95% of individuals with diabetes have type 2
diabetes [3–5], resulting from combined insulin resistance and pancreatic β-cell dysfunction
[6,7].
Recent findings from genome-wide association (GWA) studies have implicated genes which
affect pancreatic β-cell development and function in the pathogenesis of type 2 diabetes [8].
For example, the hematopoietically expressed homoebox gene (HHEX) encodes a
transcription factor involved in pancreatic development. In addition, polymorphisms in the
transcription factor 7-like 2 (TCF7L2) and potassium inwardly rectifying channel (KCNJ11)
genes may alter insulin secretion in the general population.
Apoptosis and pancreatic β-cell mass loss are recognized mechanisms of β-cell dysfunction
in type 2 diabetes [9,10]. Endoplasmic reticulum (ER) stress, due to increased demand for
insulin secretion, has been proposed as the mechanism linking insulin resistance to
pancreatic β-cell apoptosis [11–13]. ER stress and the generation of reactive oxygen species
(ROS) can lead to DNA damage and apoptosis [14]. Therefore, proteins involved in DNA
damage and repair may be causally linked to pancreatic β-cells dysfunction, β-cell apoptosis,
and the development of diabetes.
Our prior analysis of 3,153 Hypertension Genetic Epidemiology study (HyperGEN)
participants from 437 families identified evidence for linkage of type 2 diabetes to
chromosome 22 (LOD = 3.4) [15]. This signal was localized in both white (LOD = 2.0) and
African-American (LOD = 1.4) participants [15]. While several candidate genes underlie the
1 LOD unit drop support interval, we decided to first prioritize the checkpoint 2 (CHEK2)
gene that is located at 0.22 Mb from the peak of the linkage signal. CHEK2 spans 50 kb and
contains 14 exons [16]. The gene product, checkpoint kinase 2, is an important mediator of
diverse cellular responses to DNA damage, including signaling pathways of cell-cycle
control, DNA repair, and apoptosis [17,18]. To test the hypothesis that the CHEK2 gene
contains one or more polymorphic variants that are associated with type 2 diabetes, we
genotyped four single nucleotide polymorphisms (SNPs) in 1,531 white and 1,584 African-
American HyperGEN individuals (N = 38 unrelated individuals from the original linkage
study [17] were excluded from this association study). In addition, we attempted to replicate
our findings in two other Family Blood Pressure Program (FBPP) populations and in the
population-based Atherosclerosis Risk in Communities (ARIC) study.
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Family blood pressure program
The FBPP was established in 1995 to investigate the genetic determinants of high blood
pressure in multiple ethnic groups [19]. Study design and population samples have been
previously described [19]. Briefly, four networks ascertained families based on higher than
normal blood pressure levels or diagnosed hypertension. The networks used standardized
protocols and measured a standard set of 95 core phenotypes including clinical and lifestyle
information obtained by an interview [19]. A single genotyping lab typed 391 microsatellite
markers (Marshfield Genotyping Service) [19].
In this study, the HyperGEN participants constituted our primary sample. The participants
from the Genetic Epidemiology Network of Atherosclerosis (GENOA) and Gen-Net
participants were used as a replication sample. The HyperGEN study recruited African-
American and non-Hispanic white sibships with at least two members with hypertension
(blood pressure ≥ 140/90 mmHg and/or self-reported use of anti-hypertensive medications),
their offspring, and a random sample of age-and-field center matched persons from five field
centers [20]. For replication, we used the GENOA and GenNet African-American and non-
Hispanic white subjects. GENOA recruited sibships containing a minimum of two
individuals diagnosed with hypertension and first degree relatives from three field centers
[19], whereas GenNet recruited individuals with blood pressures in the upper 20–25% of the
age–gender-specific blood pressure distribution and all available first degree relatives [19].
Atherosclerosis risk in communities study
We also studied the CHEK2 polymorphisms in the population-based ARIC study. ARIC is a
prospective study of the etiology and natural history of subclinical and clinically manifest
atherosclerosis [21]. ARIC recruited 15,792 middle-aged men and women, selected as a
probability sample from four US communities [21]. Individuals were examined at
recruitment (1987–1989) and at every 3 years through January 1999. A home interview
established baseline sociodemographic and cardiovascular disease profiles. ARIC study
personnel also contact cohort members annually by telephone to establish vital status and
assess indices of cardiovascular disease, including hospitalizations. This study primarily
enrolled African-American and non-hispanic white individuals. African-Americans were
over-sampled in Forsyth County, NC and were exclusively sampled in Jackson, MS and
comprised 27% of the baseline cohort.
Diabetes and pre-diabetes outcomes
For the FBPP, serum glucose concentrations were measured using Elan Glucose reagent,
and fasting serum insulin concentrations were measured on an automated immunoassay
instrument with ultra-sensitive insulin kit from Beckman Coulter (Fullerton, CA). For
ARIC, fasting plasma glucose was determined by a hexokinase method, and fasting serum
insulin was measured using a radioimmunoassay (125Insulin Kit, Cambridge Medical
Diagnostics, Billerica, MA). In ARIC, we also used measures of fasting glucose and insulin
at Visit 1 in non-diabetic subjects for analysis of pre-diabetes states. HOMA-IR (insulin
resistance) and HOMA-beta (beta-cell function) were calculated as follows:
[Fasting insulin (mU/L) and fasting glucose (mmol/L)] [22].
North et al. Page 4













In the FBPP, individuals were classified as having prevalent type 2 diabetes if fasting
plasma glucose was at least 7.0 mmol/L (126 mg/dL) or there was current use of
medications prescribed to treat diabetes (e.g., insulin or sulfonylureas) [19]. In ARIC, as an
oral glucose tolerance test was not performed at baseline, we defined both prevalent and
incident diabetes on the basis of the following: a reported physician diagnosis, use of
glucose-lowering medications, a fasting (≥8 h) glucose of ≥7.0 mmol/l, or a non-fasting
glucose of ≥11.1 mmol/l. The date of diabetes incidence was estimated by linear
interpolation using glucose values at the ascertaining visit and the previous one, as
previously described [23].
Genotyping and SNP selection strategy
DNA extraction and storage procedures in the FBPP and ARIC studies are described
elsewhere [20]. Four tag-SNPs in the CHEK2 gene and a nearby intergenic SNP on
chromosome 22 were genotyped in HyperGEN participants. Briefly, tag-SNPs were chosen
using a pair-wise correlation (r2) of 0.65 and the HapMap Phase I CEPH sample (CEU) to
capture the majority of the then-known common variations in the gene (linkage
disequilibrium, LD, for CEPH in HapMap Phase II are shown in Supplement Fig. 1).
Genotyping for the FBPP samples was performed by the central laboratory of HyperGEN,
Salt Lake City, UT, using Taqman® SNP Genotyping Assays (Applied Biosystems, Foster
City, CA). Depending on the particular genotyping budget for each replication population,
three to four of the SNPs with the strongest effects were genotyped. The assay call rates
were 0.99 for HyperGEN and GenNet SNPs and over 0.95 for GENOA samples. In ARIC,
SNPs were genotyped at the ARIC central laboratory, Houston, TX using Taqman®
genotyping assays and the same protocol used in HyperGEN. The assay call rates for ARIC's
SNPs were over 0.95. All SNPs were tested for significant deviation from Hardy–Weinberg
equilibrium (HWE) in race-stratified samples by study population, using an alpha = 0.01. In
the family studies, HWE was tested in founders.
Statistical analysis
Assessing association in family-based studies
We used mixed models to estimate the effect of each SNP on type 2 diabetes, while
accounting for correlation within the data due to the family design and allowing for
covariate adjustment [24]. Mixed models were estimated using SAS 9.1 (PROC GLIMMIX,
SAS Institute, Cary, NC). We estimated odds ratios (ORs) and 95% confidence intervals
(CI) for type 2 diabetes. We used linear mixed models to estimate the association of SNPs
and log-transformed HOMA-IR and HOMA-beta after exclusion of individuals with
diabetes.
Assessing association among unrelated individuals
Analysis of the association of SNPs with prevalent type 2 diabetes in the ARIC study was
performed using data from the baseline clinical visit. Race-stratified prevalence odds ratios
(OR) of type 2 diabetes were calculated from logistic models, while adjusting for the effects
of age, age2, sex, age-by-sex interaction, and study center.
We also estimated the 9-year hazard ratio of type 2 diabetes associated with variants in the
CHEK2 gene using proportional hazards models. Individuals with diabetes at baseline were
excluded from the time-to-event analyses. For incident type 2 diabetes individuals, time-to-
event was measured in years from the entry date into the ARIC cohort to the date of
diagnosis. Plots of the log (−log) survival curves and the Cox test were used to assess
violations of proportional hazard assumptions.
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For analysis of HOMA-IR and HOMA-beta, we used linear regression models with additive
genetic effects adjusting for age, sex, and center after excluding individuals with diabetes.
HOMA-IR and HOMA-beta were log-transformed for analyses.
Application to FBPP and ARIC data
We tested for the independent association of each SNP with type 2 diabetes in race-stratified
samples using a general model (no mode of inheritance assumption) and an F-test (2 degrees
of freedom). Because of the cross-sectional nature of the majority of these data, a more fully
saturated adjustment strategy including factors such as body mass index, etc., was not
pursued as diabetes status may directly influence these factors.
Meta-analysis
We performed fixed effects meta-analysis of effect estimates by combining estimated
regression coefficients and standard errors across samples (STATA 10), weighting by the
inverse variance of each study [25]. We tested for the presence of between-study
heterogeneity [26].
Results
A comparison of population-specific genotype frequencies to HapMap genotype frequencies
is displayed in supplement Table 1. All allele frequencies were in HWE.
FBPP hyperGEN
The prevalence of type 2 diabetes was 14% among white and 20% among African-American
HyperGEN individuals (Table 1). We tested for the association of each SNP with type 2
diabetes in race-stratified samples adjusting for age, age2, sex, age-by-sex interaction, and
study center, while accounting for the genetic correlation among family members. Three
SNPs, rs2346397 (P = 0.005), rs4035540 (P = 0.04), and rs2078555 (P = 0.03) were
independently associated with type 2 diabetes in white HyperGEN participants. Individuals
with two copies of the risk allele for rs2346397 or rs4035540 had a twofold increased risk of
developing diabetes during the observation period in comparison with those participants
with no copies of the risk allele (Table 2). The variant rs2078555 increased the risk of
diabetes by approximately 40% for each copy of the risk allele (Table 2), whereas the
presence of two risk alleles for rs5762764 reduced the risk of diabetes by approximately
41%. None of the variants were associated with diabetes risk among African-American
HyperGEN participants (Table 2).
FBPP, GENOA and GenNet
Given the evidence of association of multiple CHEK2 SNPs with type 2 diabetes in white
HyperGEN participants, we sought to replicate our findings in two additional family-based
studies of the FBPP network, the GENOA and GenNet studies. The population
characteristics by race and the prevalence of type 2 diabetes are displayed in Table 1.
For African-American GENOA participants, we found significant associations between
rs4035540 and type 2 diabetes (P = 0.03). Two copies of the risk allele for rs4035540
increased the risk of diabetes by 84% in a model adjusted for age and sex (Table 3). In
GenNet, only three SNPs were genotyped. None of them were independently associated
with diabetes in white or African-American subjects (data not shown).
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Because of the ascertainment of the FBPP population for high blood pressure, we sought to
replicate our findings in the population-based ARIC study. Among 11,451 white and 4,091
African-American genotyped individuals, the prevalence of type 2 diabetes was 9 and 20%,
respectively (Table 1). Using logistic regression, adjusting for the effects of age, age2, sex,
age-by-sex interaction, and center, two copies of the risk allele for rs4035540 were
associated with a 66% increase in risk of diabetes among African-American individuals (P =
0.01)(Table 4 for general models). The variant rs2078555 was associated with a 25%
increase in risk of diabetes in African-Americans, however, only when comparing those
with 0 copies of the risk allele to those with 1 copy (OR 1.27, 95% CI, 1.07, 1.50, P = 0.02).
No significant associations were observed in ARIC white participants. Among 9,903 white
and 2,897 African-American ARIC participants without diabetes at baseline, 1,008 and 508
developed type 2 diabetes at 9 years of follow-up. Individual CHEK2 SNPs were not
significantly associated with incident type 2 diabetes (Table 5).
Results from the meta-analysis (Table 6) indicate that those individuals with two copies of
the risk variant for rs4035540 had a 33% increase (P = 0.02) in the risk for diabetes in all
participants, after adjusting for race, sex, age, age2, age-by-sex interaction, and center. When
stratified by race, African-Americans with two copies of the variants rs4035540 had a 57%
increase (P = 0.01) in the risk for prevalent type 2 diabetes. A summary illustration of the
results from each cohort and the meta-analysis for SNP rs4035540 is provided in Fig. 1.
In analysis of pre-diabetes traits of HOMA-IR and HOMA-beta, we found significant
associations of rs4035540 genotypes with these traits among ARIC whites only (P = 0.02
and 0.01, respectively, Supplement Table 2).
Discussion
Recent gene discoveries in type 2 diabetes have highlighted the important role of pancreatic
dysfunction in the development of the disease. Although over 14 genes have recently been
implicated in the pathogenesis of type 2 diabetes, these genetic variants explain only a small
proportion of the excess familial risk of disease in the population [8,27].
In this study, we found a significant association between several variants in the CHEK2 gene
and prevalent type 2 diabetes among white and African-American individuals. One variant,
rs4035540, was associated with increased risk for type 2 diabetes among white HyperGEN
participants, and GENOA and ARIC African-American participants. The increased risk
varied from 66 to 200%. Another variant, rs2078555, was associated with increased risk of
type 2 diabetes among white HyperGEN and African-American ARIC individuals. Two
variants, rs2346397 and rs5762764, were associated with type 2 diabetes in white
HyperGEN participants only.
Although numerous genetic tests were performed, we did not account for multiple
comparisons. However, we limited the number of statistical tests performed a priori by only
examining five CHEK2 SNPs. Given the correlation and non-independence of the SNPs and
phenotypes evaluated, a systematic correction would be extremely difficult.
While some inconsistency in replication was noted, we were limited in the coverage of the
gene by the choice of the then-available tag-SNPs. In addition, because the tag-SNPs were
selected to maximize the coverage of the gene in the CEPH HapMap population, the
coverage of the gene and pattern of LD in the participants of African descent may have been
limited. As with other identified genes for common diseases, the effect size, while probably
important, is small, and subtle variations in populations may obscure detecting a consistent
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association. Other reasons for the inconsistency in replication may include genetic
heterogeneity, gene–environment interactions, and type 1 error [8]. Nonetheless, it is
important to recognize that the association between rs4035540 was significant in the
discovery sample, in the replication populations, and in the meta-analysis, and it is unlikely
that these results could be due to chance alone. Indeed, since we did not identify a candidate
functional SNP to be typed, different SNPs, both with some LD to the causal SNP, displayed
positive association with type 2 diabetes across different populations. It is imperative that
future studies attempt to identify a causal variant for typing in future replication efforts.
We did not find significant associations of variants in CHEK2 and incident diabetes in the
ARIC cohort study. However, incident cases in the ARIC cohort were individuals who
developed diabetes between ages 45 and 70 years [28], whereas all our prevalent cases
(ARIC and FBPP) of diabetes were individuals who developed the disease between 30 and
45 years. Therefore, we may expect stronger genetic effects for early onset disease. To
further examine this possibility, we derived measures of insulin resistance (HOMA-IR) and
insulin sensitivity (HOMA-beta) in non-diabetic whites and African-Americans of the FBPP
and ARIC samples. We hypothesized that since we did not detect significant associations
between white ARIC participants and type 2 diabetes, we might detect significant
associations between these persons for impaired insulin sensitivity and/or resistance and
CHEK2 variants. Interestingly, significant associations were detected in the white ARIC
samples only (Supplement Table 2), supporting our hypothesis.
We also addressed the contribution of the identified SNP to the original linkage signal using
a maximum likelihood linkage approach that modeled affection status by a liability
threshold model as implemented in SOLAR. Adjusting for CHEK2 rs4035540 as an
additional covariate in the linkage analysis, the resulting LOD score was unchanged. While
inclusion of the SNPs in the polygenic model did not account for the previously identified
linkage peak, we were unable to genotype 38 participants from the linkage paper sample.
Thus, our inability to account for the linkage signal may reflect a reduced power due to the
exclusion of the aforementioned 38 individuals.
To further confirm our results, we evaluated the P-values from the association between SNP
genotypes and type 2 diabetes for SNPs in LD with CHEK2 rs4035540 among
approximately 2,600 participants of the Diabetes Genetic Initiative (DGI) study (formerly
available at http://www.broad.mit.edu/diabetes/). Evidence for association was observed for
CHEK2 SNP rs695388 (P = 0.014), rs9613617 (P = 0.037), rs5752764 (P = 0.023), and
rs5762763 (P = 0.035) (Supplement Table 3). These results provide confirmatory evidence
of our findings of association between CHEK2 variants and type 2 diabetes susceptibility.
Our findings suggest a role for the CHEK2 gene in susceptibility to type 2 diabetes. Our
choice of the gene was driven by its location under the 1 LOD unit drop support interval of
the linkage signal for type 2 diabetes and by the strong biological plausibility of a role of
pancreatic β-cell apoptosis in type 2 diabetes in humans [9]. Apoptosis leads to decreased β-
cell mass and therefore may contribute to exocrine pancreas dysfunction and the decreased
insulin secretion observed in individuals with type 2 diabetes [9]. ER stress can lead to DNA
damage, activating regulatory pathways that cause cell-cycle arrest and providing time for
DNA repair. CHEK2 protein is a tumor suppressor, and the link between ataxia
telangiectasia mutated (ATM) and ataxia telangiectasia RAD3-related (ATR) kinases and
checkpoint effectors in DNA repair pathway [16]. The protein structure has several
evolutionary conserved elements, with high homology among eukaryotes [16]. Mutations in
CHEK2 have been associated with sporadic and hereditary human cancers [29]. In
preliminary studies, Chung et al. showed that the CHEK2 gene null mice were transitorily
glucose intolerant, due to an inability to produce and secrete adequate amounts of insulin to
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maintain normal glucose homeostasis (personal report). The effect of CHEK2 variants in the
pathogenesis of type 2 diabetes has not been previously investigated.
In summary, we may have identified a promising type 2 diabetes candidate gene, CHEK2,
an important mediator of diverse cellular responses to DNA damage. Variants in CHEK2
may be causally linked to pancreatic β-cells apoptosis and the development of type 2
diabetes. One CHEK2 variant in particular, rs4035540, was associated with increased risk of
type 2 diabetes in HyperGEN participants and in two replication samples. Results from the
meta-analysis affirm the results for rs4035540, particularly for African-American
participants. Lastly, results from DGI provide confirmatory evidence of our findings of
association between CHEK2 variants and type 2 diabetes susceptibility. Further studies
should replicate our findings and extend these findings to closely related traits such as pre-
diabetes phenotypes, for example fasting glucose and insulin resistance so that the
underlying mechanisms of this association may be further explored.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Forest plot of the odds ratios for prevalent diabetes among White and African-American
participants of the Atherosclerosis in Communities (ARIC) and Family Blood Pressure
Program (FBPP) cohorts who are homozygote for SNP rs4035540 variant; illustrated by
cohort (circles) and in the meta-analysis (diamonds)
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Table 2
Prevalent type 2 diabetes odds ratio and 95% confidence intervals for CHEK2 SNPs by race among
HyperGEN participants
SNPs White African-American
OX versus OO XX versus OO OX versus OO XX versus OO
rs2346397 1.19 (0.84, 1.68) 2.29 (1.39, 3.77)* 0.90 (0.67, 1.22) 1.01 (0.65, 1.52)
rs4035540 1.12 (0.80, 1.56) 2.18 (1.20, 3.98)** 1.09 (0.82, 1.46) 0.97 (0.50, 1.89)
rs2078555 1.42 (1.01, 1.99)** 1.97 (1.13, 3.43)** 0.91 (0.68, 1.22) 1.00 (0.62, 1.61)
rs5762764 1.03 (0.74, 1.45) 0.59 (0.34, 0.997)** 1.06 (0.77, 1.47) 1.25 (0.54, 2.86)
Mixed models, adjusted for the family random effects and fixed effects of age, age2, sex, age-by-sex interaction, and center. X is the risk allele.
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Table 3
Prevalent type 2 diabetes odds ratio and 95% confidence intervals for CHEK2 SNPs by race among GENOA
participants
SNPs White African-American
OX versus OO XX versus OO OX versus OO XX versus OO
rs2346397 1.27 (0.89, 1.82) 1.20 (0.65, 2.22) 0.82 (0.63, 1.08) 1.24 (0.87, 1.79)
rs4035540 0.91 (0.64, 1.28) 1.35 (0.68, 2.67) 0.89 (0.69, 1.16) 1.84 (1.10, 3.06)*
rs2078555 1.28 (0.91, 1.80) 1.30 (0.74, 2.29) 1.09 (0.85, 1.41) 1.29 (0.86, 1.93)
rs5762764 0.88 (0.62,1.25) 1.18 (0.72, 1.94) 0.83 (0.62,1.12) 0.66 (0.27, 1.62)
Mixed models, adjusted for the family random effects and fixed effects of age, age2, sex, age-by-sex interaction, and center. X is the risk allele.
Referent is 00 copies. In bold, significant effects for general (2 d.f.) models at α = 0.05:
*
P = 0.03
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Table 4
Prevalent type 2 diabetes odds ratio and 95% confidence intervals for CHEK2 SNPs by race among ARIC
participants
SNPs White (N = 10,598) African-American (N = 3,436)
OX versus OO XX versus OO OX versus OO XX versus OO
rs2346397 0.93 (0.81, 1.07) 0.81 (0.64, 1.04) 1.13 (0.95, 1.35) 1.05 (0.82, 1.34)
rs4035540 0.94 (0.81, 1.08) 0.96 (0.72, 1.29) 1.02 (0.85, 1.21) 1.66 (1.18, 2.32)**
rs2078555 0.91 (0.79, 1.04) 0.83 (0.65, 1.07) 1.27 (1.07, 1.50)* 1.18 (0.88, 1.57)
rs5762764 1.09 (0.95, 1.26) 1.11 (0.91, 1.36) 1.07 (0.88, 1.30) 0.65 (0.32, 1.34)
Adjusted for the fixed effects of age, age2, sex, age-by-sex interaction, and center. X is the risk allele. Referent is 00 copies. In bold, significant
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Table 5
Incidence odds ratios and 95% confidence interval of incident type 2 diabetes by CHEK2 SNPs by race among
ARIC participants
SNPs White (N = 9,903) African-American (N = 2,897)
XO versus OO XX versus OO XO versus OO XX versus OO
rs2346397 1.05 (0.92,1.20) 1.17 (0.94,1.45) 1.03 (0.85,1.24) 1.18 (0.92,1.53)
rs4035540 1.05 (0.92,1.19) 1.13 (0.86,1.48) 1.10 (0.92,1.33) 1.24 (0.83,1.87)
rs2078555 0.99 (0.87,1.13) 1.11 (0.89,1.38) 0.92 (0.77,1.11) 0.99 (0.72, 1.36)
rs5762764 1.06 (0.93,1.22) 1.07 (0.88,1.29) 0.94 (0.76,1.18) 1.54 (0.84,2.80)
Odds ratios: Race-stratified logistic regression adjusting for the fixed effects of age, age2, sex, age-by-sex interaction, and center. X is the risk
allele. Referent is 00 copies
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